197 related articles for article (PubMed ID: 19649772)
1. Phase II study of sunitinib malate in head and neck squamous cell carcinoma.
Choong NW; Kozloff M; Taber D; Hu HS; Wade J; Ivy P; Karrison TG; Dekker A; Vokes EE; Cohen EE
Invest New Drugs; 2010 Oct; 28(5):677-83. PubMed ID: 19649772
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.
Fountzilas G; Fragkoulidi A; Kalogera-Fountzila A; Nikolaidou M; Bobos M; Calderaro J; Andreiuolo F; Marselos M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):649-60. PubMed ID: 19655144
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.
Machiels JP; Henry S; Zanetta S; Kaminsky MC; Michoux N; Rommel D; Schmitz S; Bompas E; Dillies AF; Faivre S; Moxhon A; Duprez T; Guigay J
J Clin Oncol; 2010 Jan; 28(1):21-8. PubMed ID: 19917865
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Burstein HJ; Elias AD; Rugo HS; Cobleigh MA; Wolff AC; Eisenberg PD; Lehman M; Adams BJ; Bello CL; DePrimo SE; Baum CM; Miller KD
J Clin Oncol; 2008 Apr; 26(11):1810-6. PubMed ID: 18347007
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sunitinib as second-line treatment for advanced gastric cancer.
Bang YJ; Kang YK; Kang WK; Boku N; Chung HC; Chen JS; Doi T; Sun Y; Shen L; Qin S; Ng WT; Tursi JM; Lechuga MJ; Lu DR; Ruiz-Garcia A; Sobrero A
Invest New Drugs; 2011 Dec; 29(6):1449-58. PubMed ID: 20461441
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Rini B; Redman B; Garcia JA; Burris HA; Li S; Fandi A; Beck R; Jungnelius U; Infante JR
Ann Oncol; 2014 Sep; 25(9):1794-1799. PubMed ID: 24914044
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).
Abdelraouf F; Smit E; Hasan B; Menis J; Popat S; van Meerbeeck JP; Surmont VF; Baas P; O'Brien M
Eur J Cancer; 2016 Feb; 54():35-39. PubMed ID: 26716400
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Castonguay V; Lheureux S; Welch S; Mackay HJ; Hirte H; Fleming G; Morgan R; Wang L; Blattler C; Ivy PS; Oza AM
Gynecol Oncol; 2014 Aug; 134(2):274-80. PubMed ID: 24882554
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Kaley TJ; Wen P; Schiff D; Ligon K; Haidar S; Karimi S; Lassman AB; Nolan CP; DeAngelis LM; Gavrilovic I; Norden A; Drappatz J; Lee EQ; Purow B; Plotkin SR; Batchelor T; Abrey LE; Omuro A
Neuro Oncol; 2015 Jan; 17(1):116-21. PubMed ID: 25100872
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
Han JY; Kim HY; Lim KY; Han JH; Lee YJ; Kwak MH; Kim HJ; Yun T; Kim HT; Lee JS
Lung Cancer; 2013 Feb; 79(2):137-42. PubMed ID: 23182663
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial.
Reynolds C; Spira AI; Gluck L; Bradie-Muller SJ; Zhan F; Boehm KA; Asmar L
Invest New Drugs; 2013 Oct; 31(5):1330-8. PubMed ID: 23761052
[TBL] [Abstract][Full Text] [Related]
20. Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation.
Hui EP; Ma BBY; King AD; Mo F; Chan SL; Kam MKM; Loong HH; Ahuja AT; Zee BCY; Chan ATC
Ann Oncol; 2011 Jun; 22(6):1280-1287. PubMed ID: 21317222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
